views

Previously writing on OptiBiotix Health (OPTI), earlier this month we noted prior delays in delivery from larger deals but that orders are already coming through and being booked as second half sales. Now some clear evidence of this with an announcement that the company’s GoFigure meal replacement shakes and powdered beverage shots have now been officially launched by India's Apollo Hospitals & Pharmacies.

NEWSFLOW

views

OptiBiotix Health (OPTI) has announced what it states is an important extension of its commercial experience and reach in the Asia Pacific region – with an agreement with Nutraconnect Pte., Ltd to develop and implement a market strategy there.

views

OptiBiotix Health (OPTI) has announced that it now expects half-year sales in its new structure to be materially lower than expected and, though it expects sales normalising in the second half and healthy growth next year, the current year is to now be “insufficient to make up the H1 deficit”. We profusely apologise for the short-term disappointment though, having spoken to the company, what to do now with the shares down at 20p to buy, a £17.6 million market cap?

NEWSFLOW

views

OptiBiotix Health (OPTI) has announced an update on recent scientific and commercial activities, emphasising it is “increasing the range of products, applications, and territories creating the potential to open larger market opportunities”.

views

Writing on OptiBiotix Health (OPTI) last month with the shares at 21p to buy, we noted clear news flow potential to spark the shares.  We drank our own medicine with Tom Winnifrith buying more shares in the market at c22p. They are now further up at 37p on the back of a “Joint development agreement signed with Firmenich”-titled announcement.

views

Writing on OptiBiotix Health (OPTI) last month with the shares at 21p to buy, we noted potential for a move into meaningful profitability and further potential from 'second generation' products addressing much larger market opportunities. We drank our own medicine with Tom buying more shares at 22p. The shares are now further up at 31.5p on the back of a “Joint development agreement signed with Firmenich”-titled announcement.

views

OptiBiotix Health (OPTI) has announced results for the 2021 calendar year. It continues to make progress in its stated aims: to focus on a smaller number of large partners, and grow direct-to-consumer sales.

NEWSFLOW